Transcatheter tricuspid valve implantation with the Cardiovalve system

• Published in: Future cardiology 2021-09, Vol.17 (6), p.963-969
• Main Authors: Aoi, Shunsuke, Wiley, Jose, Ho, Edwin, Goldberg, Ythan, Chau, Mei, Latib, Azeem
• Format: Article
• Language: English
• Subjects: transcatheter tricuspid valve replacement; tricuspid regurgitation
• ISSN: 1479-6678; 1744-8298
• DOI: 10.2217/fca-2020-0181

Historically considered the ‘forgotten valve’, there has been increasing attention on the percutaneous transcatheter treatment of tricuspid regurgitation (TR). Prevalence of TR is high in the elderly population and prior studies have shown worse outcomes in patients with severe TR. Advances in transcatheter-based therapies have shed a new light in the treatment of TR and one such treatment option is tricuspid valve replacement with the Cardiovalve system. This device is approved as an early feasibility study in the US and also approved for clinical study in Germany, Italy and Switzerland. The Cardiovalve device is in the early stage of clinical studies and this article reviews the existing clinical data and future studies on percutaneous transcatheter treatment of severe TR. The tricuspid valve is one of the four valves of the heart and regurgitation (the backward flow of blood) through this valve is common and associated with many diseases. Percutaneous transcatheter therapy is a treatment of this condition. A catheter (small tube) is inserted through the skin into the blood vessel without the need for invasive open-heart surgery. This nonsurgical approach has recently become more common. The Cardiovalve system is one such noninvasive therapy option for the backwards flow of blood through this valve. This article reviews the existing clinical data and provides an overview of this treatment.